Expert Opinion on Emerging Drugs

Papers
(The TQCC of Expert Opinion on Emerging Drugs is 4. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2021-02-01 to 2025-02-01.)
ArticleCitations
Emerging drugs for the treatment of alopecia areata59
Emerging drugs for the acute treatment of relapses in adult neuromyelitis optica spectrum disorder patients22
Expert opinion on emerging drugs for lung chronic graft-versus-host disease17
Emerging drugs for the treatment of hepatocellular carcinoma15
Emerging drugs in phase II and III clinical development for the treatment of alcohol use disorder14
Emerging drugs for hemophilia A: insights into phase II and III clinical trials14
Aticaprant: (a κ-opioid receptor antagonist) for major depressive disorder14
Emerging drugs for the treatment of type 1 diabetes mellitus: a review of phase 2 clinical trials12
Recent advances in uveitis therapy: focus on selected phase 2 and 3 clinical trials12
Emerging drugs for the treatment of major depressive disorder11
Emerging therapeutics in Huntington’s disease10
Emerging drugs for the preventive treatment of migraine: a review of CGRP monoclonal antibodies and gepants trials10
Emerging drugs for the treatment of myasthenia gravis9
Emerging drugs for antibody-mediated rejection after kidney transplantation: a focus on phase II & III trials9
Emerging drugs for the treatment of paroxysmal nocturnal hemoglobinuria8
A review of phase II and III drugs for the treatment and management of endometriosis7
New drugs targeting calcitonin gene-related peptide for the management of migraines7
Promising PD-1 antagonists for liver cancer: an evaluation of phase II and III results7
Is clinical trial data showing positive progress for the treatment of diabetic kidney disease?7
ONC201 (Dordaviprone): review of evidence to date in diffuse midline glioma, hope or hype?7
Emerging drugs for the treatment of postsurgical pain6
Recent advances in immune-based approaches for the treatment of esophagogastric cancer6
How promising are the latest monoclonal antibodies targeting amyloid-β for the treatment of early Alzheimer’s disease?6
Emerging monoclonal antibody therapies in the treatment of metastatic urothelial carcinoma6
Current and emerging drug treatment strategies to tackle sickle cell anemia5
Letter to the editor: ‘Emerging gene therapy products for RPGR-associated X-linked retinitis pigmentosa’5
Emerging drugs in the treatment of chronic cough5
Monoclonal antibodies in phase II and III trials for moderate to severe atopic dermatitis5
Emerging drugs for the treatment of myelofibrosis: phase II & III clinical trials5
An update on emerging drugs for the treatment of hypercholesterolemia5
A comprehensive review of phase 2/3 trials in osteoarthritis: an expert opinion5
Combined chemo-immunotherapy in advanced non-small cell lung cancer: feasible in the elderly?5
Emerging biological therapies for the treatment of malignant pleural mesothelioma4
Emerging and traditional 5-α reductase inhibitors and androgen receptor antagonists for male androgenetic alopecia4
Emerging tyrosine kinase inhibitors for head and neck cancer4
Emerging antiviral therapies and drugs for the treatment of influenza4
Emerging antibody therapies for pancreatic adenocarcinoma: a review of recent phase 2 trials4
Emerging drugs for the treatment of benign prostatic hyperplasia: a 2023 update4
Correction4
Emerging biological drugs for the treatment of gastroesophageal adenocarcinoma4
Systemic mastocytosis: 2023 update on diagnosis and management in adults4
Emerging drugs for the treatment of inflammatory bowel disease4
Treatment of idiopathic pulmonary fibrosis: an update on emerging drugs in phase II & III clinical trials4
1.0173258781433